At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,281 enrolled
Drug / intervention
Mirikizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
In Brief
A Phase 3 clinical trial evaluating Mirikizumab and Placebo for Ulcerative Colitis. Completed, enrolled 1,281 participants across 502 sites in 35 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesArgentina, Australia, Austria, Belgium, Canada, China, Croatia, Czechia, Denmark, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Poland, Romania, Russia, Serbia, Slovakia, South Korea, Spain, Switzerland, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartJun 2018
Primary CompletionJan 2021
Study CompletionMay 2024
TodayJul 2026
First PostedMay 8, 2018
Enrollment StartJun 18, 2018
Primary CompletionJan 21, 2021
Study CompletionMay 15, 2024
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 8.2 years ago
Interventions
Mirikizumabdrug
Administered IV
Placebodrug
Administered IV